KRAS and cancer: Cancer cells can develop drug resistance by acquiring novel genetic alterations that promote tumor growth, such as a novel missense mutation of the KRAS protein other than KRASG12C or at a site that affects the Switch-II pocket (S-IIP) conformation, or amplification of upstream receptor tyrosine kinases (RTKs) (19).